Theriva Biologics (Theriva Biologics) Float Percentage Of Total Shares Outstanding : 99.00% (As of Apr. 27, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Theriva Biologics's float shares is 16.98 Mil. Theriva Biologics's total shares outstanding is 17.15 Mil. Theriva Biologics's float percentage of total shares outstanding is 99.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Theriva Biologics's Insider Ownership is 38.30%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Theriva Biologics's Institutional Ownership is 2.35%.

Theriva Biologics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Theriva Biologics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	16.98	/	17.15
	=	99.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics (Theriva Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

SFY:Germany

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Executives

Steven A Shallcross	director, officer: CEO and CFO	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro	officer: Chief Operating Officer	9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan	director
Scott Tarriff	director	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman	officer: CHIEF MEDICAL OFFICER	9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp	10 percent owner	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne	officer: CHIEF FINANCIAL OFFICER	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks	director	C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr	director, officer: CEO & President	C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome	officer: Chief Scientific Officer	3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman	director
Wayne George Holman	10 percent owner	430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022